Current understanding of the structure and function of family B GPCRs to design novel drugs

被引:0
作者
Vlasios Karageorgos
Maria Venihaki
Stelios Sakellaris
Michail Pardalos
George Kontakis
Minos-Timotheos Matsoukas
Achille Gravanis
Andreas Margioris
George Liapakis
机构
[1] University of Crete,Department of Pharmacology, School of Medicine
[2] University of Crete,Department of Clinical Chemistry, School of Medicine
[3] University Hospital of Heraklion,Department of Orthopedics
[4] University of Patras,Department of Pharmacy
来源
Hormones | 2018年 / 17卷
关键词
Family B GPCRs; Ligands; Binding; Receptor activation; Antagonists; Structure; Signaling; Physiological/pathophysiological role;
D O I
暂无
中图分类号
学科分类号
摘要
Family B of G-protein-coupled receptors (GPCRs) and their ligands play a central role in a number of homeostatic mechanisms in the endocrine, gastrointestinal, skeletal, immune, cardiovascular and central nervous systems. Alterations in family B GPCR-regulated homeostatic mechanisms may cause a variety of potentially life-threatening conditions, signifying the necessity to develop novel ligands targeting these receptors. Obtaining structural and functional information on family B GPCRs will accelerate the development of novel drugs to target these receptors. Family B GPCRs are proteins that span the plasma membrane seven times, thus forming seven transmembrane domains (TM1-TM7) which are connected to each other by three extracellular (EL) and three intracellular (IL) loops. In addition, these receptors have a long extracellular N-domain and an intracellular C-tail. The upper parts of the TMs and ELs form the J-domain of receptors. The C-terminal region of peptides first binds to the N-domain of receptors. This ‘first-step’ interaction orients the N-terminal region of peptides towards the J-domain of receptors, thus resulting in a ‘second-step’ of ligand-receptor interaction that activates the receptor. Activation-associated structural changes of receptors are transmitted through TMs to their intracellular regions and are responsible for their interaction with the G proteins and activation of the latter, thus resulting in a biological effect. This review summarizes the current information regarding the structure and function of family B GPCRs and their physiological and pathophysiological roles.
引用
收藏
页码:45 / 59
页数:14
相关论文
共 568 条
  • [1] Ishihara T(1991)Molecular cloning and expression of a cDNA encoding the secretin receptor EMBO J 10 1635-1641
  • [2] Nakamura S(2003)The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol Pharmacol 63 1256-1272
  • [3] Kaziro Y(2015)The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors Br J Pharmacol 172 5744-5869
  • [4] Takahashi T(2002)Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists Trends Endocrinol Metab 13 436-444
  • [5] Takahashi K(2004)Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes J Biol Chem 279 7264-7274
  • [6] Nagata S(2014)Calcitonin gene-related peptide: physiology and pathophysiology Physiol Rev 94 1099-1142
  • [7] Fredriksson R(2002)International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors Pharmacol Rev 54 233-246
  • [8] Lagerstrom MC(2005)Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes Mol Pharmacol 67 1655-1665
  • [9] Lundin LG(2001)Receptor activity modifying proteins Cell Signal 13 73-83
  • [10] Schioth HB(2016)An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology Cell Discov 2 16020-834